Coffeng Luc E, Le Rutte Epke A, Munoz Johanna, Adams Emily, de Vlas Sake J
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam,The Netherlands.
Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel,Switzerland.
Clin Infect Dis. 2021 Jun 14;72(Suppl 3):S180-S187. doi: 10.1093/cid/ciab210.
Control of visceral leishmaniasis (VL) on the Indian subcontinent has been highly successful. Control efforts such as indoor residual spraying and active case detection will be scaled down or even halted over the coming years. We explored how after scale-down, potential recurrence of VL cases may be predicted based on population-based surveys of antibody or antigenemia prevalence.
Using a stochastic age-structured transmission model of VL, we predicted trends in case incidence and biomarker prevalence over time after scaling down control efforts when the target of 3 successive years without VL cases has been achieved. Next, we correlated biomarker prevalence with the occurrence of new VL cases within 10 years of scale-down.
Occurrence of at least 1 new VL case in a population of 10 000 was highly correlated with the seroprevalence and antigenemia prevalence at the moment of scale-down, or 1 or 2 years afterward. Receiver operating characteristic curves indicated that biomarker prevalence in adults provided the most predictive information, and seroprevalence was a more informative predictor of new VL cases than antigenemia prevalence. Thresholds for biomarker prevalence to predict occurrence of new VL cases with high certainty were robust to variation in precontrol endemicity.
The risk of recrudescence of VL after scaling down control efforts can be monitored and mitigated by means of population-based surveys. Our findings highlight that rapid point-of-care diagnostic tools to assess (preferably) seroprevalence or (otherwise) antigenemia in the general population could be a key ingredient of sustainable VL control.
在印度次大陆,内脏利什曼病(VL)的防控工作取得了巨大成功。诸如室内滞留喷洒和主动病例检测等防控措施在未来几年将逐步缩减甚至停止。我们探讨了在防控措施缩减后,如何基于基于人群的抗体或抗原血症患病率调查来预测VL病例的潜在复发情况。
我们使用VL的随机年龄结构传播模型,预测了在实现连续3年无VL病例的目标后,防控措施缩减后病例发病率和生物标志物患病率随时间的变化趋势。接下来,我们将生物标志物患病率与缩减后10年内新VL病例的发生情况进行了关联。
在10000人的人群中至少出现1例新的VL病例与缩减时或缩减后1年或2年的血清阳性率和抗原血症患病率高度相关。受试者工作特征曲线表明,成人的生物标志物患病率提供了最具预测性的信息,血清阳性率比抗原血症患病率更能预测新VL病例。预测新VL病例发生的生物标志物患病率阈值对于控制前流行程度的变化具有稳健性。
通过基于人群的调查,可以监测和减轻防控措施缩减后VL复发的风险。我们的研究结果强调,用于评估(最好是)一般人群血清阳性率或(否则)抗原血症的快速即时诊断工具可能是可持续VL控制的关键要素。